Acinar lung adenocarcinoma

Summary

Acinar lung adenocarcinoma (MONDO:0003892) is a disease. A subtype of lung adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acinar lung adenocarcinoma
Mondo ID	MONDO:0003892
DOID	DOID:6482
NCIT	C5649
UMLS	C1332137
MedGen	233130
GARD	0023717
Is cancer (heuristic)	no

Also known as: acinar adenocarcinoma of lung · acinar adenocarcinoma of the lung · acinar lung adenocarcinoma

Disease family

This is a subtype of lung adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › lung adenocarcinoma › acinar lung adenocarcinoma

Related subtypes (10): lung adenocarcinoma in situ, lung combined type small cell adenocarcinoma, lung adenoid cystic carcinoma, lung occult adenocarcinoma, minimally invasive lung adenocarcinoma, papillary lung adenocarcinoma, lung signet ring cell carcinoma, well-differentiated fetal adenocarcinoma of the lung, lung colloid adenocarcinoma, solid adenocarcinoma with mucin production

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.